Baxter moved to Neutral from Overweight at JPMorgan JPMorgan rated Baxter with a Neutral and $76 price target after being restricted on the stock since December 2012. The firm's previous rating was Overweight.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Piper Jaffray to hold a conference 25th Annual Healthcare Conference is being held in New York on December 3-4 with webcasted company presentations to begin on December 3 at 8 am; not all company presentations may be webcasted. Webcast Link